This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The test is intended for the detection of COVID-19 infection, either a recent or previous infection, as detected through an adaptive antibody immuneresponse to SARS-CoV-2. The test involves self-collection of a fingerstick dried blood sample.
Adaptive Biotechnologies’ T-Detect COVID Test is a next-generation sequencing (NGS) test that can indicate recent or prior infection with SARS-CoV-2 through detection of a T cell immuneresponse to the virus. This is the first T cell test of its kind for the detection of COVID-19 infection.
All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immuneresponses following the second dose of INO-4800.
The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immuneresponses. It will be funded by the U.S.
It was recently reported that the addition of an adjuvant to their vaccine led to enhanced immuneresponses that exceeded responses in convalescent serum from symptomatic COVID-19 patients. Novavax has also tested its recombinant SARS-CoV-2 nanoparticle adjuvanted vaccine in a Phase I/II trial.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content